RPH develops and produces drugs in the form of kits that are “bound” to radioactive elements (radioisotopes), forming a final radiopharmaceutical. The technology is used in examinations and treatments in Nuclear Medicine. In 2020, the company was acquired by The Ygeia Medical Group.
